We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+18.45%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.11B
AUM Growth
+$203M
Cap. Flow
+$116M
Cap. Flow %
10.49%
Top 10 Hldgs %
77.46%
Holding
28
New
8
Increased
10
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$83.1M
2
MDXG icon
MiMedx Group
MDXG
+$73.1M
3
NUVA
NuVasive, Inc.
NUVA
+$38.3M
4
CORT icon
Corcept Therapeutics
CORT
+$34.4M
5
URGN icon
UroGen Pharma
URGN
+$32.6M

Top Sells

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$79M
2
MYGN icon
Myriad Genetics
MYGN
+$71.4M
3
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$60.2M
4
KERX
Keryx Biopharmaceuticals Inc
KERX
+$37.1M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$24M

Sector Composition

Rank Sector Weight
1 Healthcare 92.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
26
PTC Therapeutics
PTCT
$6.26B
– –
-3,946,009
Closed -$79M
KERX
27
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-5,229,455
Closed -$37.1M
AAAP
28
DELISTED
Advanced Accelerator Applications S.A.
AAAP
– –
-890,935
Closed -$60.2M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Consonance Capital Management held 28 positions worth $1.11B, up 22% from $904M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Consonance Capital Management deployed $116M of net new capital in Q4 2017, opening 8 new positions and adding to 10 existing holdings. Its largest new stake was Radius Health, Inc.: 2,649,285 shares worth $84.2M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Spectrum Pharmaceuticals Inc, an estimated $24M trimmed.

  • Consonance Capital Management's largest Q4 2017 buy was Radius Health, Inc.: 2,649,285 shares worth $84.2M.
  • Consonance Capital Management added most to Corcept Therapeutics in Q4 2017, an estimated $34.4M increase.
  • Consonance Capital Management's biggest Q4 2017 reduction was Spectrum Pharmaceuticals Inc, cutting an estimated $24M.
  • Consonance Capital Management fully exited PTC Therapeutics in Q4 2017, selling an estimated $79M.
  • Consonance Capital Management's ten largest holdings make up 77% of its $1.11B portfolio in Q4 2017.
  • Consonance Capital Management opened 8 new positions and closed 5 in Q4 2017.
  • Consonance Capital Management's portfolio value rose 22% quarter-over-quarter to $1.11B.

Based on Consonance Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.